Annexa 4 trial6/5/2023 ![]() ![]() Major limitations, particularly the lack of information on bleeding severity, impedes the ability to draw strong conclusions, however. Among patients hospitalized with life-threatening or uncontrolled bleeding related to direct factor Xa inhibition, in-hospital and 30-day mortality vary based the type of reversal agent used, with andexanet alfa (Andexxa Portola Pharmaceuticals) associated with the lowest rates, two studies show. ![]()
0 Comments
Leave a Reply. |